Literature DB >> 21178454

Abnormal CEACAM6 expression in Crohn disease patients favors gut colonization and inflammation by adherent-invasive E. coli.

Nicolas Barnich1, Arlette Darfeuille-Michaud.   

Abstract

Abnormal expression of CEACAM6 is observed at the apical surface of the ileal epithelium in Crohn's disease (CD) patients, and CD ileal lesions are colonized by pathogenic adherent-invasive Escherichia coli (AIEC). The paper of Carvalho et al. recently reported that CD associated AIEC colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM6 acting as a receptor for type 1 pili produced by AIEC bacteria. AIEC also induce CEACAM6 expression by intestinal epithelial cells directly by adhering to host cells and indirectly via increased secretion of TNF-α from AIEC-infected macrophages. Patients expressing a basal level of CEACAM6 in ileum could be predisposed to develop ileal CD and blocking interaction between type 1 pili and CEACAM6 might serve as a specific means of disrupting the colonization and the subsequent inflammatory amplification loop.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21178454     DOI: 10.4161/viru.1.4.11510

Source DB:  PubMed          Journal:  Virulence        ISSN: 2150-5594            Impact factor:   5.882


  14 in total

Review 1.  The intestinal microbiota: its role in health and disease.

Authors:  Luc Biedermann; Gerhard Rogler
Journal:  Eur J Pediatr       Date:  2015-01-07       Impact factor: 3.183

2.  CEACAMs serve as toxin-stimulated receptors for enterotoxigenic Escherichia coli.

Authors:  Alaullah Sheikh; Brunda Tumala; Tim J Vickers; David Alvarado; Matthew A Ciorba; Taufiqur Rahman Bhuiyan; Firdausi Qadri; Bernhard B Singer; James M Fleckenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-02       Impact factor: 11.205

Review 3.  Changes of intestinal microbiota and microbiota-based treatments in IBD.

Authors:  Qianyu Li; Siyu Zhou; Yanna Wang; Jing Cong
Journal:  Arch Microbiol       Date:  2022-07-01       Impact factor: 2.552

4.  Diet and Inflammatory Bowel Disease.

Authors:  Karina Knight-Sepulveda; Susan Kais; Rebeca Santaolalla; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-08

Review 5.  Precision antimicrobial therapeutics: the path of least resistance?

Authors:  Caitlin N Spaulding; Roger D Klein; Henry L Schreiber; James W Janetka; Scott J Hultgren
Journal:  NPJ Biofilms Microbiomes       Date:  2018-02-27       Impact factor: 7.290

6.  Genetic Diversity and Virulence Determinants of Escherichia coli Strains Isolated from Patients with Crohn's Disease in Spain and Chile.

Authors:  Sandra Céspedes; Waleska Saitz; Felipe Del Canto; Marjorie De la Fuente; Rodrigo Quera; Marcela Hermoso; Rául Muñoz; Daniel Ginard; Sam Khorrami; Jorge Girón; Rodrigo Assar; Ramón Rosselló-Mora; Roberto M Vidal
Journal:  Front Microbiol       Date:  2017-05-24       Impact factor: 5.640

7.  Characteristics and pathogenic role of adherent-invasive Escherichia coli in inflammatory bowel disease: Potential impact on clinical outcomes.

Authors:  Jae Gon Lee; Dong Soo Han; Su Vin Jo; A Reum Lee; Chan Hyuk Park; Chang Soo Eun; Yangsoon Lee
Journal:  PLoS One       Date:  2019-04-29       Impact factor: 3.240

Review 8.  Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease.

Authors:  Ahmed Tawfik; Paul K Flanagan; Barry J Campbell
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

9.  Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer.

Authors:  Maelle Prorok-Hamon; Melissa K Friswell; Abdullah Alswied; Carol L Roberts; Fei Song; Paul K Flanagan; Paul Knight; Caroline Codling; Julian R Marchesi; Craig Winstanley; Neil Hall; Jonathan M Rhodes; Barry J Campbell
Journal:  Gut       Date:  2013-07-11       Impact factor: 23.059

10.  Characterizing CEACAM5 interaction with CD8α and CD1d in intestinal homeostasis.

Authors:  G Roda; X Jianyu; M S Park; L DeMarte; Z Hovhannisyan; R Couri; C P Stanners; G Yeretssian; L Mayer
Journal:  Mucosal Immunol       Date:  2013-10-09       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.